Oppenheimer analyst Kostas Biliouris has lowered the price target for Alnylam Pharmaceuticals (ALNY) from $500 to $350, while maintaining an 'Outperform' rating. This significant price target reduction, despite the maintained positive rating, suggests a re-evaluation of the company's near-term valuation or growth prospects by the analyst.
Oppenheimer analyst Kostas Biliouris maintained an 'Outperform' rating on Alnylam Pharmaceuticals but drastically cut the price target from $500 to $350. This action indicates that while the analyst still sees long-term potential in ALNY, there are likely revised expectations regarding its short-to-medium term growth trajectory, competitive landscape, or pipeline progress that warrant a lower valuation. For traders, this could signal a period of increased volatility for ALNY as the market digests the analyst's revised outlook, potentially leading to short-term downward pressure despite the 'Outperform' rating. The key risk is that other analysts may follow suit, further impacting investor sentiment.